NCT02959957View on ClinicalTrials.gov

Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections

PHASE4CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

May 20, 2016

Primary Completion Date

August 31, 2019

Study Completion Date

August 31, 2019

Conditions
Urinary Tract Infections
Interventions
DRUG

Temocillin

Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.

DRUG

Cefotaxime

Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.

Trial Locations (12)

83131

Östersund Hospital, Östersund

171 76

Karolinska University Hospital, Solna

251 87

Helsingborg Hospital, Helsingborg

291 85

Centralsjukhuset Kristianstad, Kristianstad

581 85

Linköping University Hospital, Linköping

221 85

Skåne University Hospital, Lund

601 82

Vrinnevisjukhuset i Norrköping, Norrköping

701 85

Örebro University Hospital, Örebro

112 81

Capio S:t Görans hospital, Stockholm

856 43

Sundsvall Hospital, Sundsvall

901 85

University Hospital of Umeå, Umeå

721 89

Västmanlands sjukhus i Västerås, Västerås

All Listed Sponsors
lead

Håkan Hanberger

OTHER_GOV

NCT02959957 - Disturbance of the Intestinal Microbiota by Temocillin vs Cefotaxime in Treatment of Febrile Urinary Tract Infections | Biotech Hunter | Biotech Hunter